Publication: Entecavir Treatment of Chronic Hepatitis D
Program
Authors
Authors
Kabacam, Gokhan
ÖNDER, Fatih Oğuz
Yakut, Mustafa
Seven, GÜLSEREN
Karatayli, Senem C.
Karatayli, Ersin
Savas, Berna
Idilman, Ramazan
Bozdayi, A. Mithat
Yurdaydin, Cihan
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Background. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).
Description
Source:
Keywords:
Keywords
Citation
Kabacam G., ÖNDER F. O. , Yakut M., Seven G., Karatayli S. C. , Karatayli E., Savas B., Idilman R., Bozdayi A. M. , Yurdaydin C., -Entecavir Treatment of Chronic Hepatitis D-, CLINICAL INFECTIOUS DISEASES, cilt.55, ss.645-650, 2012